Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis.
about
Role of bioactive fatty acids in nonalcoholic fatty liver diseaseDiet, Microbiota, Obesity, and NAFLD: A Dangerous QuartetProbiotics as Complementary Treatment for Metabolic DisordersMultiple hits, including oxidative stress, as pathogenesis and treatment target in non-alcoholic steatohepatitis (NASH)Induction of peroxisomes by butyrate-producing probioticsThe Influence of the Gut Microbiota on Host Physiology: In Pursuit of MechanismsAntioxidant Properties of Probiotic Bacteria.Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH)Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver diseaseFructo-oligosaccharides and intestinal barrier function in a methionine-choline-deficient mouse model of nonalcoholic steatohepatitis.Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model.Gut microbiome and metabolic diseases.Differential modulation of innate immunity in vitro by probiotic strains of Lactobacillus gasseriEffects of Clostridium butyricum on antioxidant properties, meat quality and fatty acid composition of broiler birds.A breakthrough in probiotics: Clostridium butyricum regulates gut homeostasis and anti-inflammatory response in inflammatory bowel disease.Gut-liver axis, nutrition, and non-alcoholic fatty liver diseaseEffect of dietary supplementation of Bacillus subtilis B10 on biochemical and molecular parameters in the serum and liver of high-fat diet-induced obese mice.Flesh Shear Force, Cooking Loss, Muscle Antioxidant Status and Relative Expression of Signaling Molecules (Nrf2, Keap1, TOR, and CK2) and Their Target Genes in Young Grass Carp (Ctenopharyngodon idella) Muscle Fed with Graded Levels of CholineImpact of increasing fruit and vegetables and flavonoid intake on the human gut microbiota.Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials.Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?Disparate metabolic effects of blackcurrant seed oil in rats fed a basal and obesogenic diet.Gut microbiota-associated bile acid deconjugation accelerates hepatic steatosis in ob/ob mice.Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota.De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucoseRole of toll-like receptors in immune activation and tolerance in the liver.Role of Nrf2 in chronic liver disease.The role of butyrate, a histone deacetylase inhibitor in diabetes mellitus: experimental evidence for therapeutic intervention.Bacillus amyloliquefaciens SC06 alleviates the oxidative stress of IPEC-1 via modulating Nrf2/Keap1 signaling pathway and decreasing ROS production.Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases.Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia.Impact of Hypocaloric Hyperproteic Diet on Gut Microbiota in Overweight or Obese Patients with Nonalcoholic Fatty Liver Disease: A Pilot Study.Gastrodin Ameliorates Oxidative Stress and Proinflammatory Response in Nonalcoholic Fatty Liver Disease through the AMPK/Nrf2 Pathway.Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet.Preventing subclinical necrotic enteritis through Lactobacillus johnsonii BS15 by ameliorating lipid metabolism and intestinal microflora in broiler chickens.Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH).Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implicationsAnti-diabetic Effects of Clostridium butyricum CGMCC0313.1 through Promoting the Growth of Gut Butyrate-producing Bacteria in Type 2 Diabetic Mice.
P2860
Q26739904-1921517D-DDFE-485B-8995-C31CD4C1C6B8Q26752614-D8CF8F43-E715-4AE2-8105-4D7FCA2BB959Q26795371-1BFBC9C0-CB1A-45F5-9CCE-9123B26E5631Q27007515-E5B75695-0500-419B-8AC5-F92F0AC095F2Q27315125-5E177AB4-DA31-4D60-B7A8-07E557600D6DQ28070162-CB4DC0A8-6438-4D33-A1AD-8F763780963CQ33749630-7743B52E-349A-4B96-B303-ED0CB861E4D0Q33755566-FCA77DD2-97B0-4E62-8CC1-D712C23739D6Q33780172-9746E6D1-1E72-4803-B447-0A12B66B3444Q33817253-B7E67BFF-E160-4734-AD32-791F99BC687BQ34499017-C9100A66-1581-4AC1-A551-EC8C6B79B265Q34589677-08BD6D88-16D5-4B0A-A89A-1FD5ED1D3342Q34731373-B5267C0B-B5D0-4AF6-AEAE-A2FCE1105506Q35033105-49D6F539-9C4A-4492-93C3-39320452AE4DQ35074765-11D170A2-7571-42BE-9B27-3C0D416BBBBEQ35538800-D4497533-059F-4BCE-B632-46A5CA381F2EQ35621970-7AEDD8A7-C65F-4778-B73A-0106D18F3669Q35685083-905F9E95-AC76-4522-B402-1049D476D15AQ35753767-17274832-5369-4D78-AC23-E83FF7E1239BQ35850746-DB1C84A0-49D9-45A5-8B07-090EA7105877Q35891840-FC5EDC66-34E3-4D00-85EC-E3CBD28053FAQ35920786-C23A43A6-6F8E-491A-A28C-3858B0844A9BQ35947349-7504C554-AEB9-4548-9552-03E2877704C9Q35967988-A6652011-FC54-4448-9250-B185CAA27D99Q35998233-AE7806FF-B951-42A4-B1FC-48BCCF9EE10AQ36148926-120B0FFE-5298-4499-A72A-7BD179E75704Q36800168-35FA2802-E854-44A1-8AA0-33955020769AQ38218115-C3600B35-C7CE-4C1F-8D18-7E908D2D819DQ38256342-C16C78D6-85DE-429A-8849-6F6FCD3A213EQ38537774-59C13C34-3BCD-4400-8471-B91070366273Q38726500-CBFEA22F-C7D9-4E99-9828-567FC3650F9FQ38742951-FC8455FF-AC83-4738-B0D7-6E7B7259145CQ38743021-61EE8B31-D9D1-4C7A-8395-6F5E20C99711Q38872043-74B29589-5030-4E79-9625-85D19DAA217AQ38935541-0FFA56A5-C957-44BD-BB8C-E5B32378BD0EQ39180593-312A527F-C0B2-4E01-A261-D7234B9B17ABQ40156166-CB306DD4-011F-4B82-AB39-8E0A1FE4AA89Q40450653-1E1F131E-9B82-447D-90DA-FA466EF5F28CQ41036794-94DA0FA1-D7E7-4EF5-8A8A-2F2B40086F29Q41203575-5356C70F-B99C-435C-86A8-6358775489BA
P2860
Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: new insight into the probiotics for the gut-liver axis.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Butyrate-producing probiotics ...... iotics for the gut-liver axis.
@ast
Butyrate-producing probiotics ...... iotics for the gut-liver axis.
@en
Butyrate-producing probiotics ...... iotics for the gut-liver axis.
@nl
type
label
Butyrate-producing probiotics ...... iotics for the gut-liver axis.
@ast
Butyrate-producing probiotics ...... iotics for the gut-liver axis.
@en
Butyrate-producing probiotics ...... iotics for the gut-liver axis.
@nl
prefLabel
Butyrate-producing probiotics ...... iotics for the gut-liver axis.
@ast
Butyrate-producing probiotics ...... iotics for the gut-liver axis.
@en
Butyrate-producing probiotics ...... iotics for the gut-liver axis.
@nl
P2093
P2860
P1433
P1476
Butyrate-producing probiotics ...... iotics for the gut-liver axis.
@en
P2093
Hitoshi Endo
Maki Niioka
Mamoru Tanaka
Noriko Kobayashi
Tetsu Watanabe
P2860
P304
P356
10.1371/JOURNAL.PONE.0063388
P407
P577
2013-05-16T00:00:00Z